视网膜疾病玻璃体内治疗的演变——从巨细胞病毒到脉络膜新生血管:第74届爱德华·杰克逊纪念讲座
本文为回顾性文献综述与个人视角,梳理过去25年视网膜疾病玻璃体内治疗的发展:更昔洛韦首次用于慢性视网膜疾病的重复玻璃体内注射,随后曲安奈德用于糖尿病性黄斑水肿、贝伐珠单抗用于新生血管性年龄相关性黄斑变性;CATT是首个玻璃体内治疗对比疗效试验,其持续影响当今实践;治疗负担、费用和工作流程影响显著。
要点
- 玻璃体内抗生素治疗眼内炎使眼科医生熟悉了这种给药方式,通常为一次性使用。
- 更昔洛韦是首个广泛可用、相对便宜的复合药物,用于重复玻璃体内注射治疗慢性视网膜疾病。
- 更昔洛韦被制成缓释给药制剂以避免频繁注射,而抗VEGF药物实现这一目标更为困难。
核心结论
- 玻璃体内治疗已被证明对许多视网膜疾病的治疗高度有效。
- 患者因多次注射承受的治疗负担、对医疗系统的费用以及对临床工作流程的影响均相当大。
- 开发有效、降低治疗负担和费用的玻璃体内治疗的努力正在进行中。
研究设计与样本
- 回顾性文献综述与个人视角。
主要发现
- 过去25年视网膜疾病的药物治疗进展显著,几乎所有新开发的高效药物都需要玻璃体内给药,导致每年玻璃体内注射次数呈指数增长。
- 玻璃体内抗生素注射治疗眼内炎通常为一次性使用,首先使眼科医生熟悉了这种给药方式。
- 更昔洛韦是首个广泛可用、相对便宜的复合药物,用于重复玻璃体内注射治疗慢性视网膜疾病,随后曲安奈德用于糖尿病性黄斑水肿、贝伐珠单抗用于新生血管性年龄相关性黄斑变性。
- 更昔洛韦被制成缓释给药制剂以避免频繁玻璃体内注射,这一目标对抗VEGF药物而言更为困难。
- 开展评估这些治疗的部分试验时遇到重大政治障碍,解决其提出的问题带来了重要的国家政策变化,将影响未来临床试验的实施。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To present the evolution of intravitreal therapy for retinal diseases and its impact on clinical practice. DESIGN: Retrospective literature review and personal perspective. METHODS: Retrospective literature review and personal perspective. RESULTS: Pharmacotherapeutic advances in retinal disease have been remarkable over the last 25 years. Almost all of the new drugs developed have required intravitreal administration to be highly effective, leading to an exponential increase in the annual number of intravitreal injections given. The use of intravitreal antibiotic injections to treat endophthalmitis, usually on a one-time basis, first familiarized ophthalmologists with this method of drug delivery. Ganciclovir was the first widely available, relatively inexpensive compounded drug that was used for repeat intravitreal injection to treat a chronic retinal disease, followed by triamcinolone for diabetic macular edema and bevacizumab for neovascular age-related macular degeneration. Ganciclovir was formulated for sustained-release drug delivery to avoid frequent intravitreal injections, a goal that has been more elusive for anti-VEGF drugs. Political obstacles encountered while conducting some of the trials to evaluate these treatments were substantial. Addressing the issues they raised led to important national policy changes that will impact the conduct of future clinical trials. The first comparative efficacy trial of intravitreal therapies was the Comparison of AMD Treatments Trials (CATT). The primary results from CATT and the many publications that followed continue to shape the use of intravitreal therapy today. CONCLUSION: Intravitreal therapy has proven highly effective for the treatment of many retinal diseases. The treatment burden for patients from numerous injections, the cost to health care systems, and the impact on workflows in clinical practice have been substantial. Efforts to develop effective intravitreal therapies with reduced treatment burden and cost are ongoing.
引用
- Martin DF. Evolution of Intravitreal Therapy for Retinal Diseases-From CMV to CNV: The LXXIV Edward Jackson Memorial Lecture. Am J Ophthalmol. 2018. PMID: 29339063. doi:10.1016/j.ajo.2017.12.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。